secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2022-07-19T23:59:59+00:00
Accession:  0001193125-22-196582
Event type: litigation
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal subsidiary settles Opana ER antitrust litigation for $265M; records Q2 charge
--------------------------------------------------------------------------------

- Impax subsidiary agrees to pay $265M plus interest to settle Opana ER antitrust class actions.
- Settlement covers direct purchaser, indirect purchaser, and individual claims in MDL.
- Company to record pre-tax charge of approx. $265M in Q2 2022.
- Payments to be made between 2022 and Jan 2024; funded by cash on hand, cash flow, and revolver.
- Settlement is not an admission of liability; subject to court approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312522196582/0001193125-22-196582-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312522196582/d320133d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-196582

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer